Milestone Pharmaceuticals (NASDAQ:MIST) COO Sells $23,632.85 in Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) COO Jeffrey Edward Nelson sold 12,245 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $1.93, for a total value of $23,632.85. Following the transaction, the chief operating officer directly owned 49,848 shares of the company’s stock, valued at approximately $96,206.64. This trade represents a 19.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jeffrey Edward Nelson also recently made the following trade(s):

• On Monday, December 15th, Jeffrey Edward Nelson sold 58,007 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $2.32, for a total transaction of $134,576.24.

Milestone Pharmaceuticals Stock Performance

Shares of MIST stock opened at $1.91 on Friday. Milestone Pharmaceuticals Inc. has a 12 month low of $0.63 and a 12 month high of $3.06. The company’s fifty day simple moving average is $2.22 and its 200-day simple moving average is $1.97. The firm has a market cap of $162.67 million, a PE ratio of -2.33 and a beta of 0.44. The company has a quick ratio of 8.24, a current ratio of 8.24 and a debt-to-equity ratio of 2.74.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.05. Equities research analysts expect that Milestone Pharmaceuticals Inc. will post -0.62 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on MIST. Weiss Ratings reissued a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen downgraded Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Milestone Pharmaceuticals in a report on Tuesday, January 6th. Zacks Research upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 26th. Finally, Wells Fargo & Company lifted their price objective on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Milestone Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $8.00.

Institutional Trading of Milestone Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. Valeo Financial Advisors LLC grew its stake in Milestone Pharmaceuticals by 553.5% in the 2nd quarter. Valeo Financial Advisors LLC now owns 130,699 shares of the company’s stock valued at $254,000 after buying an additional 110,699 shares during the last quarter. Simplify Asset Management Inc. boosted its holdings in shares of Milestone Pharmaceuticals by 16.5% during the second quarter. Simplify Asset Management Inc. now owns 990,000 shares of the company’s stock worth $1,921,000 after acquiring an additional 140,000 shares during the period. Creative Planning grew its position in shares of Milestone Pharmaceuticals by 74.6% in the second quarter. Creative Planning now owns 23,410 shares of the company’s stock valued at $45,000 after purchasing an additional 10,000 shares during the last quarter. XTX Topco Ltd grew its position in shares of Milestone Pharmaceuticals by 209.5% in the second quarter. XTX Topco Ltd now owns 160,963 shares of the company’s stock valued at $312,000 after purchasing an additional 108,959 shares during the last quarter. Finally, Raymond James Financial Inc. increased its stake in shares of Milestone Pharmaceuticals by 30.1% during the second quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock worth $84,000 after purchasing an additional 10,000 shares during the period. Institutional investors and hedge funds own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.